Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc has demonstrated a positive trajectory in market share growth, attributed to its effective go-to-market strategy and the high quality of its products, particularly Jeuveau and Evolysse. The company has experienced a significant rise in customer engagement, with a 30% year-over-year increase in the Evolus Rewards loyalty program and over 3,000 accounts purchasing Evolysse, reflecting a robust customer base. Financially, Evolus reported toxin revenue of $82 million, a 4% increase year-over-year, while management indicated a commitment to achieving sustainable profitability, with expectations of a doubling of revenue in 2025, alongside stabilizing toxin procedure volumes.

Evolus Inc. is facing a negative outlook due to a range of macroeconomic and operational challenges, including a deteriorating consumer spending environment, inconsistent commercial execution, and heightened competition, which have contributed to its lower long-term financial projections. The company has revised its 2028 revenue expectations from at least $700 million to a range of $450 million to $500 million, translating to a reduced compound annual growth rate of 15%-19% and a decline in anticipated non-GAAP operating income margins from at least 20% to 13%-15%. Furthermore, ongoing concerns about supply chain issues, potential tariffs, and negative clinical data updates further exacerbate the risks surrounding Evolus, indicating that previous growth expectations in the aesthetics market may not materialize as initially anticipated.